Asia
Lisheng Pharmaceutical Flags Sharp Decline in H1 Profit
Tianjin Lisheng Pharmaceutical (SHE:002393) expects attributable net profit of 730 million yuan to 830 million yuan for the first half of 2026, down 76% to 79% from 3.43 billion yuan in the year-earlier period, according to a Wednesday Hong Kong bourse filing by parent Tianjin Development (HKG:0882).Basic earnings per share are expected to range between 0.23 yuan and 0.28 yuan, compared with 1.11 yuan a year earlier.The company attributed the expected decline to a higher comparison base from dividends received from Tasly Group in the prior-year period, as well as lower revenue and profit resulting from centralized, volume-based pharmaceutical procurement and product price reductions.
HKG:0882SHE:002393
